The high ratio of cost-to-effectiveness in preventing RSV in infants by both vaccinating the expectant mother and giving the infant a preventative monoclonal antibody likely means that a dual approach is out of the question in most cases, but figuring out which maternal-child pairs should get which product could also be quite burdensome on the US health care system.
Key Takeaways
- CDC working group suggests there are few cases where both maternal RSV vaccination and infant monoclonal antibody protection are needed, though neither product seems to be clearly preferential.
If both RSVpreF, Pfizer Inc.’s maternal respiratory syncytial virus vaccine, and AstraZeneca PLC/Sanofi’s nirsevimab gain US Food...
